Carisma Therapeutics Inc. buy melinda
Start price
05.05.19
/
50%
€22.73
Target price
20.05.19
€39.69
Performance (%)
34.13%
End price
20.05.19
€30.49
Summary
This prediction ended on 20.05.19 with a price of €30.49. The BUY prediction by melinda for Carisma Therapeutics Inc. saw massive gains of 34.13%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Carisma Therapeutics Inc. | -1.651% | -1.651% | -86.824% | -96.753% |
iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
According to melinda what are the pros and cons of Carisma Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Sesen Bio Inc diskutieren
Secteur Recherche biotechnologique et médicale Agenda 13/05 Publication de résultats
Sesen Bio, Inc, anciennement Eleven Biotherapeutics, Inc, une société clinique en phase terminale qui fournit une plate-forme de thérapie protéique ciblée (TPT). La Société se concentre sur le développement des anticorps-médicaments conjugués (ADC) pour le traitement du cancer. Son portefeuille de produits comprend Vicinium, Vicinium en combinaison avec un inhibiteur de contrôle de contrôle, durvalumab et VB6-845d. Le programme principal de la Société, Vicinium, ainsi que la poursuite de la phase III de développement du traitement du cancer de la vessie non invasive et non musculaire (NMIBC). Il cible les antigènes de la molécule d'adhésion des cellules épithéliales (EpCAM) à la surface de la cellule tumorale pour libérer une cytotoxine puissante, les exotoxines A de Pseudomonas (ETA), directement aux cellules cancéreuses.
Nombre d'employés
: 17 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Carisma Therapeutics Inc.
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€16.58
16.10.21
16.10.21
-
16.10.22
16.10.22
22.56%
24.10.21
24.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.55
16.10.21
16.10.21
-
16.10.22
16.10.22
-
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.55
16.10.21
16.10.21
-
16.10.22
16.10.22
-
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.55
16.10.21
16.10.21
-
16.10.22
16.10.22
-
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€15.44
12.10.21
12.10.21
-
12.10.22
12.10.22
7.38%
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€73.80
17.06.21
17.06.21
€50.00
17.06.22
17.06.22
-66.50%
17.08.21
17.08.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€18.58
21.08.20
21.08.20
€30.00
04.11.21
04.11.21
297.12%
17.06.21
17.06.21
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€34.10
21.05.19
21.05.19
€45.10
21.08.20
21.08.20
-45.50%
21.08.20
21.08.20
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€26.34
31.10.18
31.10.18
€31.57
07.11.18
07.11.18
6.16%
07.11.18
07.11.18
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€13.35
19.11.17
19.11.17
€21.65
03.01.18
03.01.18
16.91%
03.01.18
03.01.18
Could be worthwhile Investment >10% per year
Carisma Therapeutics Inc.
Start price
Target price
Perf. (%)
€47.45
10.07.16
10.07.16
€54.12
25.07.16
25.07.16
20.50%
25.07.16
25.07.16
Could be worthwhile Investment >10% per year